The federal monopoly on growing cannabis for research has officially ended, with two companies telling news sources that they’ve harvested their first Drug Enforcement Administration-approved crops in recent weeks.
For more than 50 years, only a single facility at the University of Mississippi has been permitted under a federal agreement to grow marijuana for study purposes. In recent years, DEA said it would be taking steps to end that monopoly and authorize additional manufacturers. Several companies received conditional approvals for their applications in May.
Two of those companies—Groff North America Hemplex and the Biopharmaceutical Research Company (BRC)—say they’ve officially received registrations from DEA and have started growing and harvesting plants.
Researchers say this development represents a significant step forward, with DEA making initial moves to oversee the production of research-grade cannabis on a scale that hasn’t been seen before.
Kentucky’s Senate majority floor leader—who owns a bourbon company called “Kentucky Senator”—said he opposes medical cannabis despite strong support from his constituents.
“If they don’t like it, they can take it out on me in the next election.”
Kentucky Democratic Senate candidate Charles Booker tweeted, “There is overwhelming bipartisan support to legalize medical cannabis in Kentucky. The politicians blocking it know that very well.”
Mississippi’s lieutenant governor pushed back against Gov. Tate Reeves’s (R) criticism of pending medical cannabis legislation, while the House speaker said it is “not the top issue” for the session. Separately, a senator is proposing a medical marijuana bill that would ban smoking.
https://www.supertalk.fm/hosemann-fires-back-at-reeves-regarding-medical-marijuana/
Massachusetts’s top marijuana regulator said implementing delivery services can “take a big chunk out of” the illegal market.
Quebec, Canada’s government is denying access to marijuana and alcohol retail locations to people who have not received COVID vaccinations.
A study concluded that medical cannabis “use for chronic pain is increasing with cannabis legalization.”
A study of mice suggested that “both cannabinoids and terpenes in oil extracts should be considered as potential therapeutic agents against epileptic seizures and epilepsy.”
source
